Tyme Technologies (NASDAQ:TYME) and Bellerophon Therapeutics (NASDAQ:BLPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.
This is a summary of current ratings and recommmendations for Tyme Technologies and Bellerophon Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares Tyme Technologies and Bellerophon Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
19.8% of Tyme Technologies shares are owned by institutional investors. Comparatively, 54.7% of Bellerophon Therapeutics shares are owned by institutional investors. 27.2% of Tyme Technologies shares are owned by company insiders. Comparatively, 53.1% of Bellerophon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Volatility & Risk
Tyme Technologies has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Bellerophon Therapeutics has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500.
Valuation and Earnings
This table compares Tyme Technologies and Bellerophon Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Tyme Technologies||N/A||N/A||-$32.98 million||($0.32)||-3.25|
|Bellerophon Therapeutics||N/A||N/A||$2.81 million||($0.34)||-2.03|
Tyme Technologies is trading at a lower price-to-earnings ratio than Bellerophon Therapeutics, indicating that it is currently the more affordable of the two stocks.
Bellerophon Therapeutics beats Tyme Technologies on 7 of the 10 factors compared between the two stocks.
Tyme Technologies Company Profile
Tyme Technologies, Inc., a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM. INOpulse is based on proprietary pulsatile nitric oxide delivery device. BCM is based on placebo-controlled clinical trial designed to support CE mark registration in the European Union. Bellerophon Therapeutics was founded in 2009 and is headquartered in Warren, NJ.
Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.